CN103145834B - 一种抗体人源化改造方法 - Google Patents
一种抗体人源化改造方法 Download PDFInfo
- Publication number
- CN103145834B CN103145834B CN201310016799.9A CN201310016799A CN103145834B CN 103145834 B CN103145834 B CN 103145834B CN 201310016799 A CN201310016799 A CN 201310016799A CN 103145834 B CN103145834 B CN 103145834B
- Authority
- CN
- China
- Prior art keywords
- antibody
- humanization
- sequence
- epitope
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310016799.9A CN103145834B (zh) | 2013-01-17 | 2013-01-17 | 一种抗体人源化改造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310016799.9A CN103145834B (zh) | 2013-01-17 | 2013-01-17 | 一种抗体人源化改造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103145834A CN103145834A (zh) | 2013-06-12 |
CN103145834B true CN103145834B (zh) | 2015-03-18 |
Family
ID=48544198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310016799.9A Active CN103145834B (zh) | 2013-01-17 | 2013-01-17 | 一种抗体人源化改造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103145834B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105277638A (zh) * | 2014-07-22 | 2016-01-27 | 沈鹤霄 | 一种单克隆抗体IgG质谱测序方法 |
CN104403001B (zh) * | 2014-12-12 | 2018-01-16 | 中国人民解放军南京军区军事医学研究所 | 一种全人源抗TLR4的抗体Fab及其全分子抗体IgG和应用 |
CN110021342B (zh) * | 2017-08-21 | 2020-12-15 | 北京哲源科技有限责任公司 | 用于加速变异位点的识别的方法及系统 |
CN107446047B (zh) * | 2017-09-04 | 2020-08-11 | 山西省生物研究院有限公司 | 一种双功能性抗组织因子人源化抗体及其制备方法 |
CN107779500A (zh) * | 2017-10-25 | 2018-03-09 | 上海药明生物技术有限公司 | 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列 |
CN109337930B (zh) * | 2018-09-30 | 2020-10-30 | 北京鼎成肽源生物技术有限公司 | 一种afft1细胞 |
CN111394475A (zh) * | 2020-03-26 | 2020-07-10 | 迈杰转化医学研究(苏州)有限公司 | 一种核苷酸组合物、包含其的检测试剂盒及其应用 |
CN112365919A (zh) * | 2020-12-01 | 2021-02-12 | 北京迈迪培尔信息技术有限公司 | 一种基于遗传算法的抗体计算优化方法 |
CN113393899A (zh) * | 2021-05-26 | 2021-09-14 | 江苏普瑞康生物医药科技有限公司 | 基于动态规划的抗体人源化的方法与装置 |
CN115458048B (zh) * | 2022-09-16 | 2023-05-26 | 杭州美赛生物医药科技有限公司 | 基于序列编解码的抗体人源化方法 |
WO2024088381A1 (zh) * | 2022-10-28 | 2024-05-02 | 南京金斯瑞生物科技有限公司 | 人源化抗体序列评估模型的构建方法及其应用 |
CN115975028B (zh) * | 2022-11-02 | 2023-08-29 | 厦门康基生物科技有限公司 | 一种孕酮抗体、制备方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050491A2 (en) * | 2004-11-08 | 2006-05-11 | Epitomics, Inc. | Methods for antibody engineering |
CN101928345A (zh) * | 2010-06-21 | 2010-12-29 | 中国科学技术大学 | 一种人源化抗体及其人源化改造方法 |
CN102863533A (zh) * | 2010-06-21 | 2013-01-09 | 中国科学技术大学 | 抗体人源化改造方法 |
-
2013
- 2013-01-17 CN CN201310016799.9A patent/CN103145834B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050491A2 (en) * | 2004-11-08 | 2006-05-11 | Epitomics, Inc. | Methods for antibody engineering |
CN101928345A (zh) * | 2010-06-21 | 2010-12-29 | 中国科学技术大学 | 一种人源化抗体及其人源化改造方法 |
CN102863533A (zh) * | 2010-06-21 | 2013-01-09 | 中国科学技术大学 | 抗体人源化改造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103145834A (zh) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103145834B (zh) | 一种抗体人源化改造方法 | |
Adolf-Bryfogle et al. | RosettaAntibodyDesign (RAbD): A general framework for computational antibody design | |
Van Regenmortel et al. | Specificity, polyspecificity and heterospecificity of antibody-antigen recognition | |
Xu et al. | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 | |
Sela-Culang et al. | The structural basis of antibody-antigen recognition | |
Taka et al. | Critical interactions between the SARS-CoV-2 spike glycoprotein and the human ACE2 receptor | |
ES2387585T3 (es) | Procedimiento de uso en anticuerpos monoclonales que se adaptan al ser humano | |
Li et al. | OptMAVEn–a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes | |
US20170206308A1 (en) | Method of computational protein design | |
Rantalainen et al. | Co-evolution of HIV envelope and apex-targeting neutralizing antibody lineage provides benchmarks for vaccine design | |
JP2017531443A (ja) | Vh−vlドメイン間角度に基づく抗体ヒト化の方法 | |
Margreitter et al. | Antibody humanization by molecular dynamics simulations—in‐silico guided selection of critical backmutations | |
Townsend et al. | Augmented binary substitution: single-pass CDR germ-lining and stabilization of therapeutic antibodies | |
Rouet et al. | Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies | |
Sevy et al. | Antibodies: Computer‐aided prediction of structure and design of function | |
Finton et al. | Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 | |
Zhang et al. | A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation | |
Kuroda et al. | Antibody affinity maturation by computational design | |
Callaway et al. | Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium | |
Teixeira et al. | Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs | |
CN109415441A (zh) | 抗体及其制备方法 | |
Talavera et al. | Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody | |
Borowska et al. | Biochemical and biophysical characterization of natural polyreactivity in antibodies | |
CA2875200A1 (en) | Fibrosis suppression by inhibiting integrin alpha8beta1 function | |
Xiang et al. | Super-immunity by broadly protective nanobodies to sarbecoviruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171211 Address after: Zhuhai Avenue, Guangdong city of Zhuhai province Jinwan District 519000 No. 6366 Building No. 6 on the eastern side of the first to the three layer Co-patentee after: GUANGZHOU TAINUODI BIOTECHNOLOGY Co.,Ltd. Patentee after: ZHUHAI TRINOMAB BIOTECHNOLOGY Co.,Ltd. Address before: 510300 Guangzhou International Biological Island spiral Road, No. 1, office area, unit 207, Guangdong Patentee before: GUANGZHOU TAINUODI BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180320 Address after: Zhuhai Avenue, Guangdong city of Zhuhai province Jinwan District 519000 No. 6366 Building No. 6 on the eastern side of the first to the three layer Patentee after: ZHUHAI TRINOMAB BIOTECHNOLOGY Co.,Ltd. Address before: Zhuhai Avenue, Guangdong city of Zhuhai province Jinwan District 519000 No. 6366 Building No. 6 on the eastern side of the first to the three layer Co-patentee before: GUANGZHOU TAINUODI BIOTECHNOLOGY Co.,Ltd. Patentee before: ZHUHAI TRINOMAB BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 519090 room 110, first floor, plant 6, No. 6366, Zhuhai Avenue, Jinwan District, Zhuhai City, Guangdong Province Patentee after: Zhuhai Tainuo Maibo Pharmaceutical Co.,Ltd. Address before: 519000 the first to three floors east of 6 building, 6366 Zhuhai Avenue, Zhuhai, Guangdong. Patentee before: ZHUHAI TRINOMAB BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |